Reversal of abnormal coronary vasomotion by calcium antagonists in patients with hypercholesterolemia.
BACKGROUND
It has been shown that exercise-induced coronary vasodilation of angiographically normal coronary vessels is reduced in hypercholesterolemic patients. The purpose of this study was to evaluate the effect of calcium channel blockers on coronary vasomotion of angiographically smooth coronary arteries in hypercholesterolemic patients.


RESULTS
A total of 57 patients were included in the present analysis. Vasomotion of angiographically normal coronary arteries was evaluated in 37 control subjects (group 1) without and 20 patients (group 2) with calcium blocker administration before physical exercise. Both groups were subdivided into subgroup A (normal cholesterol values: < or = 5.5 mmol/L or 212 mg%) and subgroup B (elevated cholesterol values: >5.5 mmol/L or 212 mg%). Coronary luminal area at rest and during exercise was assessed by biplane quantitative coronary angiography. The normal vessels showed a significant increase in coronary luminal area during exercise in subgroup A (n=13) with normal cholesterol values (31%; P<.05) but not in subgroup B (n=24; 13%; P=NS). In contrast, all patients in group 2 showed similar vasodilation during exercise, namely, 22% (P<.05) in subgroups A (n=8) and B (n=12) (P<.05). Independent of the actual cholesterol level, the stenotic lesions showed coronary vasoconstriction during exercise in group 1 but vasodilation in group 2 after pretreatment with calcium antagonists.


CONCLUSIONS
Coronary vasomotor response to exercise is inversely related to actual serum cholesterol level in angiographically normal vessels. Administration of calcium antagonists normalizes exercise-induced vasodilation and thus eliminates cholesterol-induced abnormal vasomotion, probably by a direct effect on the smooth muscles of the vasculature.
Kaufmann
P A
PA
Division of Cardiology, University Hospital, Zurich, Switzerland.
Frielingsdorf
J
J
Mandinov
L
L
Seiler
C
C
Hug
R
R
Hess
O M
OM
D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D016022:Case-Control Studies; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000187:drug effects*; D004110:Diltiazem / Q000627:therapeutic use*; D005080:Exercise Test; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000627:therapeutic use*; D016896:Treatment Outcome; D014666:Vasomotor System / Q000187:drug effects*
D002121:Calcium Channel Blockers; D009529:Nicardipine; D004110:Diltiazem